Gendell Jeffrey L’s Avadel Pharmaceuticals AVDL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-4,769,357
| Closed | -$103M | – | 103 |
|
|
2025
Q4 | $103M | Sell |
4,769,357
-545,453
| -10% | -$10.6M | 1.79% | 3 |
|
|
2025
Q3 | $81.2M | Buy |
5,314,810
+138,199
| +3% | +$1.8M | 1.49% | 2 |
|
|
2025
Q2 | $45.8M | Sell |
5,176,611
-950,545
| -16% | -$8.35M | 1.22% | 2 |
|
|
2025
Q1 | $48M | Sell |
6,127,156
-203,279
| -3% | -$1.7M | 2.07% | 2 |
|
|
2024
Q4 | $66.5M | Buy |
6,330,435
+524,995
| +9% | +$6.38M | 2.08% | 4 |
|
|
2024
Q3 | $76.1M | Buy |
5,805,440
+65,297
| +1% | +$995K | 2.39% | 3 |
|
|
2024
Q2 | $80.7M | Buy |
5,740,143
+32,025
| +0.6% | +$522K | 2.82% | 4 |
|
|
2024
Q1 | $96.4M | Buy |
5,708,118
+92,768
| +2% | +$1.38M | 3.72% | 5 |
|
|
2023
Q4 | $79.3M | Hold |
5,615,350
| – | – | 4.31% | 5 |
|
|
2023
Q3 | $57.8M | Buy |
5,615,350
+219,290
| +4% | +$2.94M | 3.29% | 6 |
|
|
2023
Q2 | $88.9M | Buy |
5,396,060
+94,146
| +2% | +$1.22M | 6.9% | 3 |
|
|
2023
Q1 | $48.6M | Buy |
5,301,914
+181,309
| +4% | +$1.49M | 4.55% | 4 |
|
|
2022
Q4 | $36.7M | Buy |
5,120,605
+334,278
| +7% | +$2.34M | 3.25% | 6 |
|
|
2022
Q3 | $24M | Buy |
4,786,327
+527,631
| +12% | +$2.9M | 3.14% | 7 |
|
|
2022
Q2 | $10.4M | Buy |
4,258,696
+1,421,265
| +50% | +$5.84M | 1.2% | 13 |
|
|
2022
Q1 | $19.4M | Buy |
2,837,431
+391,132
| +16% | +$2.69M | 1.39% | 15 |
|
|
2021
Q4 | $19.8M | Buy |
2,446,299
+387,529
| +19% | +$3.54M | 1.6% | 11 |
|
|
2021
Q3 | $20.2M | Buy |
2,058,770
+22,656
| +1% | +$178K | 1.73% | 8 |
|
|
2021
Q2 | $13.7M | Buy |
2,036,114
+102,277
| +5% | +$812K | 1.21% | 10 |
|
|
2021
Q1 | $17.5M | Buy |
1,933,837
+252,446
| +15% | +$2.04M | 1.86% | 5 |
|
|
2020
Q4 | $11.2M | Buy |
1,681,391
+566,180
| +51% | +$3.54M | 1.52% | 7 |
|
|
2020
Q3 | $5.62M | Buy |
1,115,211
+73,373
| +7% | +$534K | 1.18% | 8 |
|
|
2020
Q2 | $8.42M | Buy |
1,041,838
+488,322
| +88% | +$4.31M | 2.15% | 4 |
|
|
2020
Q1 | $4.39M | Sell |
553,516
-593,248
| -52% | -$4.56M | 1.35% | 7 |
|
|
2019
Q4 | $8.66M | Buy |
1,146,764
+777,038
| +210% | +$4.1M | 1.11% | 15 |
|
|
2019
Q3 | $1.54M | Buy |
+369,726
| New | +$926K | 0.22% | 43 |
|
Other funds holding AVDL
Gendell Jeffrey L's AVDL Position: Q1 2026 in Review
Gendell Jeffrey L sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 4,769,357 shares — an estimated $103M sold.
Gendell Jeffrey L first reported a position in AVDL in Q3 2019 and held it in 26 quarters. The position peaked at $103M in Q4 2025. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.
- Gendell Jeffrey L reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
- Gendell Jeffrey L sold 4,769,357 Avadel Pharmaceuticals shares in Q1 2026, an estimated $103M.
- Gendell Jeffrey L first reported a position in Avadel Pharmaceuticals in Q3 2019 and held it in 26 quarters.
- Gendell Jeffrey L's Avadel Pharmaceuticals position peaked at $103M in Q4 2025.
- 2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.
Based on Gendell Jeffrey L's 13F filing for Q1 2026, filed 15 May 2026.